Q3 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Novartis submission schedule New Molecular Entities: Lead and supplementary indications Lead Supplementary 2023 iptacopan LNP023 PNH 38 Investor Relations | Q3 2023 Results 2024 atrasentan EXV811 IgAN opnurasib JDQ443 2/3L NSCLC (mono) remibrutinib LOU064 CSU sabatolimab MBG453 HR-MDS iptacopan LNP023 C3G iptacopan LNP023 IgAN PluvictoⓇ AAA617 mCRPC, Pre-taxane PluvictoⓇ AAA617 MHSPC E 2025 pelacarsen TQJ230 CVRR-Lp(a) Appendix Innovation: Clinical trials References Abbreviations INNOVATION Cardiovascular Immunology Neuroscience Oncology Non-core TA project ≥2026 177 Lu-NeoB AAA603 Multiple Solid Tumors. ianalumab VAY736 2L Immune Thrombocytopenia iscalimab CFZ533 Sjögren's syndrome ligelizumab QGE031 Food allergy LNA043 Knee osteoarthritis rapcabtagene autoleucel YTB323. High-risk large B-cell lymphoma TNO155 Solid tumors XXB750 Hypertension zigakibart FUB523 IgAN cipargamin KAE609 Malaria severe ganaplacide/lumefantrine KLU156 Malaria uncomplicated LXE408 Visceral leishmaniasis ianalumab VAY736 1L Immune Thrombocytopenia ianalumab VAY736 WAIHA ianalumab VAY736 AIH ianalumab VAY736 Sjögren's syndrome cipargamin KAE609 Malaria uncomplicated ianalumab VAY736 Lupus Nephritis ianalumab VAY736 SLE iptacopan LNP023 aHUS iptacopan LNP023 IC-MPGN opnurasib JDQ443 NSCLC (Combo) rapcabtagene autoleucel YTB323 Lupus Nephritis remibrutinib LOU064 Multiple sclerosis remibrutinib LOU064 Sjögren's syndrome remibrutinib LOU064 CINDU sabatolimab MBG453 Unfit AML D D © NOVARTIS | Reimagining Medicine

View entire presentation